Compare Fiverr International Ltd (FVRR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Fiverr International Ltd trades at $8.72 (market cap $310.61M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 32.5× Fiverr International Ltd's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FVRR | XBI | |
|---|---|---|
Market Cap | $310.61M | $10.11B |
Volume | 381,459 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $23.60 | $169.55 |
52-Week Low | $8.47 | $104.99 |
Typical Hold Time | 62 Days | 38 Days |
Enterprise Value | $63.00M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.64, up 1.65% on the day, amid a bearish technical outlook with recent earnings misses in Q1 and Q2 2026. Revenue for 2025 reached $430.91M with a net income margin of 7.18%, though 2026 revenue is projected to dip to $418M. Valuation ratios appear attractive with a P/E of 10.67 and P/S of 0.76, but the stock faces headwinds from AI disruption compressing demand for freelance services, as highlighted in recent news.
The stock's outlook is cautious, with analyst consensus leaning Hold (76.47%) and a price target of $10.50 offering potential upside. Key risks include AI-driven market shifts and competitive pressures, while the current low valuation may appeal to value investors if the company navigates transitional challenges successfully.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
